1Division of Transplantation and Vascular Surgery, Department of Surgery, Chonnam National University Hospital, Gwangju Korea
2 Co-First Author
Hong Sung Jung, Young Woo Chung, Ho Kyun Lee, Sang Young Chung, Soo Jin Na Choi, (2024). Splenic Artery Aneurysm. Clinical Cardiovascular Research. 3(2); DOI: 10.58489/2836-5917/022
© 2024 Hong Sung Jung, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Splenic artery aneurysms, Endovascular treatment, Complication
Purpose: Splenic artery aneurysm (SAA) is uncommon disease. Reported SAAs are increased because of advanced radiological diagnostic modalities. The aim of this study is to analyze of clinical findings of SAAs and to evaluate of endovascular therapies of SAAs.
Materials and Methods: We retrospectively reviewed medical records of 37 consecutive SAA from June 2009 to May 2023. 37 patients were treated by endovascular interventions with coils, plugs, stents and stent grafts.
Results: 37 patients (9 males, 29 females) involved in the study with mean age was 58.1 years. Mean age for male was 69.8years. Mean age for female was 56.3years. 32 patients were diagnosis incidentally. 5 cases were complained abdominal pain. There was 3 pseudoaneurysms and 33 cases were saccular type. 4 patients were had 2 aneurysms. Mean aneurysm size was 2.4cm. Dome to neck ratio range was 1.6 to 2.8. Coil embolizations were performed in 25 cases and plug embolizations in 4 cases. 8 endovascular treatments of SAA with a stent graft. 4 complications were noted. There was 1 endoleak and treated by additional stent. Distal flow of splenic artery was not noted in 3 patients. 2 patients showed splenic infarction. 1 focal infarction patient was recovery after 1 year. Other 34 patients had no complications. There was no splenic artery aneurysm associated mortality.
Conclusion: In endovascular era, with the development of modern endovascular technologies, endovascular treatment of SAAs should be attempted as first line treatment, especially in ruptured aneurysms and even if relatively asymptomatic small aneurysms.
Aneurysms is defined as an artery with an increased 50% diameter of artery than expected and result in mortality and morbidity [1,2]. Splenic artery aneurysm (SAA) is uncommon. Large autopsy study revealed that an incidence of SAA is between 0.01 and 0.98%. The prevalence of SAA is not clear because most of SAA is asymptomatic [3]. Now more often diagnosed due to the increased use of cross-sectional imaging and an aging population [4,5]. Rare but clinically important vascular condition because of potential life-threatening disease. Recently SAA is extreme challenge in both emergency diagnosis and treatment. SAA is the most frequent visceral artery aneurysms, constituting 50–70% of visceral artery aneurysms [6]. In addition, SAA is the third most frequent intraabdominal aneurysms, following abdominal aorta and iliac artery aneurysms [6,7].
We retrospectively reviewed medical records of 37 consecutive SAA from June 2009 to May 2023. 37 patients were treated by endovascular interventions with coils, plugs, stents and stent grafts. The study protocol was approved by the Institutional Review Board of Chonnam National University Hospital. This study was exempted from written informed consent due to retrospective analysis based on medical records by Institutional Review Board. The 3D-derived method uses Synapse picture archiving and communication system (PACS) updates to automatically calculate the volume of contrast within an aneurysm. After importing CT angiogram series into Synapse, a 3D reconstruction of the aneurysm is formed. Aneurysms is defined as an artery with an increased 50% diameter of adjacent artery. Statistical analysis was performed using IBM SPSS Statistics ver 19.0 software (IBM Co., Armonk, NY, USA). Continuous data were compared using the student’s t-test and Fisher exact tests.
78 patients (9 males, 69 females) involved in the study with mean age was 58.1 years. Mean age for male was 69.8years and age range was 51 to 80 years. Mean age for female was 56.3 and age range was 26 to 77 years. 32 patients were diagnosis incidentally. 5 cases were complained abdominal pain. 1 case under the impression of metastatic hepatocellular carcinoma and she has two fusiform type of SAAs [Fig1]. This case was symptom aggravated and grave prognosis. Other 4 patients were improved symptom after endovascular intervention. There was 3 pseudoaneurysms [Fig2] and 33 cases were saccular type. 4 patients were had 2 aneurysms. Mean aneurysm size was 2.4cm and aneurysm size range was 1.2 to 7.2cm. Dome to neck ratio range was 1.6 to 2.8. At last follow up period, mean aneurysm size was 2.3cm in 25 patients. 3 patients had a limited increasing in the diameter of its SAA sac after coil embolization. 11 patients had calcified aneurysm wall [Fig3]. In location of splenic artery aneurysms were extrasplenic 27 cases, juxtasplenic 3 cases and hilar 7 cases. Coil embolizations were performed in 25 cases and plug embolizations in 4 cases. 8 endovascular treatments of SAA with a stent graft. 4 complications were noted. There was 1 endoleak during the stent grafting and treated by additional stent [Fig4]. Distal flow of splenic artery was not noted in 3 patients. 2 patients showed splenic infarction. 1 focal infarction patient was recovery after 1year [Fig5]. Other 34 patients had no complications. There was no splenic artery aneurysm related mortality.
Fig1. (A) Digital subtraction angiogram demonstrated two fusiform SAAs.
Fig1 (B) SAAs were treated by multiple coils and plugs embolizations.
Fig2. (A) Digital subtraction angiogram demonstrated pseudoaneurysm.
Fig2 (B) Pseudoaneurysm was excluded by stent-graft.
Fig3. (A) Angiography showed 7.2cm sized SAA with calcified aneurysm wall(arrow).
Fig3. (B) There was no flow disturbance after coil embolization.
Fig4. (A) Angiography showed endoleak after stent graft.
Fig4. (B) This endoleak was treated by additional stent.
Fig5. Spleen focal infarction was recovery after 1 year.
Etiological factor of true SAA is unclear, but arteriosclerosis [6], portal hypertension [8,9], multiparity, medial degeneration [10,11], and fibromuscular dysplasia [12]. Other etiological factors of false or pseudoSAAs are intra-abdominal infectious or inflammatory conditions [7,13], and vasculitis, surgery, iatrogenic intervention, and trauma [14]. Mortality rates in rupture of SAA is 40% [1]. Such high mortality rate is depending on location, etiology, and other contributing factors. Determination of rupture risk is primarily by diameter of SAA (aneurysmal size). Rupture rate of splenic artery is between 3% to 10% [15]. Treatment options of SAAs are elective repair, observation, and emergent repair. The goal of SAA treatment is preventing rupture and exsanguination. Treatment modalities of SAAs are surgical treatment and endovascular intervention. Consideration factor of determination of treatment modalities are patient characteristics (age, gender, presence of comorbidities), aneurysm characteristics (size, anatomic location), collateral circulation and pathogenesis [16]. Surgical management of SAA is viable alternative in the endovascular area. Laparoscopic for splenic artery aneurysms was performed [17]. Methods of surgical treatment are aneurysmectomy and bypass grafting [18,19], aneurysmectomy and end-to-end anastomosis [20], and ligation [21]. Treatment modalities of endovascular treatment are deployment of coils and glue, particle or gelfoam injection, placement of covered stents, flow-diverting stents (FDS), and stent graft [22,23]. Open surgery shift to endovascular intervention. Marked changes in treatment modalities occurred over the past decade with the advent of endovascular therapies. Immediate benefits of endovascular therapy are shorter hospital stay, local anesthesia and/or conscious sedation use, avoidance of major incisions, faster recovery, and patients with comorbidities prohibitive to open surgical management [24]. Drawbacks of endovascular therapy are access-related injury, contrast toxicity, end-organ embolization, and need for prolonged postembolization imaging surveillance [24]. The choice of treatment modality is individualized to the clinical scenario, and optimal results can be achieved with knowledge of the endovascular armamentarium. Endovascular embolization therapy use nitinol coils, cyanoacrylate glue, plug, and stent graft [23]. Often limited by relatively large aneurysmal size and wide-necked splenic artery aneurysm treated using neurovascular comaneci neck-bridging device [25]. Open and endovascular approaches have similar rates of technical and clinical success, as well as mortality during follow-up. However, periprocedural morbidity was significantly higher in cases treated by open surgery. Although longer-term follow-up is needed to access the durability of the endovascular treatment, initial successful outcomes and low reintervention rates make it a safe and feasible approach. Conventionally indications of splenic artery aneurysm the presence of a symptomatic aneurysm regardless its diameter or of an asymptomatic aneurysm with a maximum diameter larger then 2cm and in persons undergoing liver transplantation [26]. In endovascular era, with the development of modern endovascular technologies, endovascular treatment of SAAs should be attempted as first line treatment, especially in ruptured aneurysms and even if relatively asymptomatic small aneurysms.